Boston Scientific Corp. (BSX) showed mixed performance in the market, with stock occasionally underperforming compared with competitors. BSX, however, surpassed Q2 earnings and revenue estimates, recording GAAP EPS of $0.22 and revenue of $4.120 billion. Factors contributing to this performance include strong delivery from the Watchman device, a focus on global expansion and innovation, and robust cardiovascular devices demand growth. BSX faced rising costs and competition, yet, proven by a 2x rise in profits, the firm appears to handle these challenges effectively. With the acquisition of Silk Road Medical for $1.16 billion and the proposed purchase of Axonic, Inc., BSX continues to concentrate on strategic mergers and acquisitions to increase growth. The company seems confident in its performance, raising the FY24 outlook and issuing Q3 2024 earnings guidance. With this, stock analysts have increased BSX's price target, between $86 and $91. Despite occasional low market days, the company consistently achieved a significant share price momentum, and its shareholder earned a 13% CAGR over the last five years.
Boston Scientific Corp BSX News Analytics from Mon, 08 Jan 2024 08:00:00 GMT to Sun, 28 Jul 2024 21:18:00 GMT -
Rating 5
- Innovation 4
- Information 9
- Rumor -4
